AstraZeneca, Oxford Vaccine Up to 90% Effective in Late-Stage Trials

LONDON—The Covid-19 vaccine being developed by the University of Oxford and AstraZeneca PLC was found to be as much as 90% effective in preventing infections without serious side effects in a large clinical trial in the U.K. and Brazil, the partners said Monday.

Efficacy ranged from 62% to 90% depending on dosage given, AstraZeneca and Oxford said.

AstraZeneca…

This post first appeared on wsj.com